BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
Last month’s EU approval of Vazkepa -- a treatment derived from fish oil and branded…
The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in…
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month…
Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its…
When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled…
The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with…
The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in…
Companies developing sustainable meat and dairy alternatives smashed records with a €2.6B ($3.1B) haul last…
As barely a third of European countries meet targets to track concerning Covid-19 variants, diagnostics…
A €62M Series B round announced by the Belgian company AgomAb Therapeutics last week is…